Advances in molecular genetics have made it plausible to correct many heritable and acquired disorders by strategically placing corrected or correcting copies of the causative genes in patients with these types of disease, termed gene therapy. Expectations for gene therapy are great, this because of the considerable press generated by the many gene therapy trials (>100) in the United States and because every week disease are being defined at the genetic and molecular level. Unfortunately, to date every few patients have benefitted from gene therapy. This has led to harsh criticism of those who advocate gene therapy. Despite the criticisms gene therapy continues to have huge therapeutic potential. The genesis of this program project arose from our observation, in 1991, that the enthusiasm for the application of gene therapy was ahead of the science of the details. It was this anticipation that led to our proposing to bring definition to the potential as well the limitations of gene therapy with cells of the skin. Much has been learned; new as well as old challenges mark the field. The current state of understanding has caused us to not focus on a disease, rather it addresses those elements that are key to bringing gene therapy with cells of the skin to the clinic in the near future. The governing hypothesis directing this renewal is: gene therapy with cells of the skin can be successfully utilized on a broad range of diseases once there is an understanding of expression and non expression of transgenes introduced into cells of the skin. Four projects are directed at this governing hypothesis. The theme of Project 1 is to define the basis for the continued expression of transgenes by cells in vitro and loss in vivo, and to test the concept that immortalized genetic modified keratinocytes have therapeutic potential. The theme of Project 2 is to test the concept that keratinocytes bearing transgenes which over-express immunosuppressive factors can be used to develop a """"""""universal"""""""" epidermal allograft. The theme of Project 3 is to understand mechanisms by which gene products are transported out of skin and targeted to tissues and to devise strategies to enhance the activity and persistence of therapeutic gene products. The theme of Project 4 is to develop proof of principle and establish the parameters of the external regulation of transgenes of genetically modified cells of the skin. These projects will be supported by: administrative, cell culture/tissue reconstruction and transgene Cores.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Program Projects (P01)
Project #
5P01HD028528-09
Application #
6476767
Study Section
Special Emphasis Panel (ZHD1-MCHG-B (KG))
Program Officer
Moody, Sally Ann
Project Start
1992-04-01
Project End
2003-11-30
Budget Start
2001-12-01
Budget End
2002-11-30
Support Year
9
Fiscal Year
2002
Total Cost
$1,181,915
Indirect Cost
Name
University of Utah
Department
Dermatology
Type
Schools of Medicine
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Davis, Howard E; Rosinski, Matthew; Morgan, Jeffrey R et al. (2004) Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J 86:1234-42
Erdag, Gulsun; Medalie, Daniel A; Rakhorst, Hinne et al. (2004) FGF-7 expression enhances the performance of bioengineered skin. Mol Ther 10:76-85
Erdag, Gulsun; Morgan, Jeffrey R (2004) Allogeneic versus xenogeneic immune reaction to bioengineered skin grafts. Cell Transplant 13:701-12
Woodley, David T; Krueger, Gerald G; Jorgensen, Cynthia M et al. (2003) Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 121:1021-8
Erdag, Gulsun; Morgan, Jeffrey R (2002) Interleukin-1alpha and interleukin-6 enhance the antibacterial properties of cultured composite keratinocyte grafts. Ann Surg 235:113-24
Hamoen, Karen E; Morgan, Jeffrey R (2002) Transient hyperproliferation of a transgenic human epidermis expressing hepatocyte growth factor. Cell Transplant 11:385-95
Davis, Howard E; Morgan, Jeffrey R; Yarmush, Martin L (2002) Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. Biophys Chem 97:159-72
DeWitt, Ann; Iida, Tomoko; Lam, Ho-Yan et al. (2002) Affinity regulates spatial range of EGF receptor autocrine ligand binding. Dev Biol 250:305-16
Gill, Pritmohinder S; Krueger, Gerald G; Kohan, Donald E (2002) Doxycycline-inducible retroviral expression of green fluorescent protein in immortalized human keratinocytes. Exp Dermatol 11:266-74
Erdag, Gulsun; Morgan, Jeffrey R (2002) Survival of fetal skin grafts is prolonged on the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient mouse/skin allograft model. Transplantation 73:519-28

Showing the most recent 10 out of 42 publications